JPWO2020146344A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146344A5 JPWO2020146344A5 JP2021539435A JP2021539435A JPWO2020146344A5 JP WO2020146344 A5 JPWO2020146344 A5 JP WO2020146344A5 JP 2021539435 A JP2021539435 A JP 2021539435A JP 2021539435 A JP2021539435 A JP 2021539435A JP WO2020146344 A5 JPWO2020146344 A5 JP WO2020146344A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mrna
- seq
- glycero
- dnah5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 90
- 108020004999 Messenger RNA Proteins 0.000 claims description 60
- 229920002106 messenger RNA Polymers 0.000 claims description 60
- 101710031971 DNAH5 Proteins 0.000 claims description 25
- 102100017497 DNAH5 Human genes 0.000 claims description 25
- 229920001320 Leader sequence (mRNA) Polymers 0.000 claims description 22
- 239000002502 liposome Substances 0.000 claims description 20
- 229920001405 Coding region Polymers 0.000 claims description 18
- 125000002091 cationic group Chemical group 0.000 claims description 16
- -1 DLenDMA Chemical compound 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 13
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 11
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 claims description 10
- KILNVBDSWZSGLL-KXQOOQHDSA-O 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-O 0.000 claims description 8
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 8
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 claims description 8
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-Methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 8
- REZZEXDLIUJMMS-UHFFFAOYSA-M Dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 claims description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 8
- 229920000401 Three prime untranslated region Polymers 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 6
- 210000004072 Lung Anatomy 0.000 claims description 6
- 230000001809 detectable Effects 0.000 claims description 6
- 210000000979 Axoneme Anatomy 0.000 claims description 5
- NEZDNQCXEZDCBI-WJOKGBTCSA-N (2-aminoethoxy)[(2R)-2,3-bis(tetradecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-WJOKGBTCSA-N 0.000 claims description 4
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 claims description 4
- ZKWQSBFSGZJNFP-UHFFFAOYSA-N 1,2-Bis(dimethylphosphino)ethane Chemical compound CP(C)CCP(C)C ZKWQSBFSGZJNFP-UHFFFAOYSA-N 0.000 claims description 4
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-Bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims description 4
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 4
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 4
- XIWUJDSJKCVNRX-UGKPPGOTSA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-prop-1-ynyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(C#CC)O[C@H](CO)[C@@H](O)[C@H]1O XIWUJDSJKCVNRX-UGKPPGOTSA-N 0.000 claims description 4
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 claims description 4
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 claims description 4
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 claims description 4
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 claims description 4
- SHCCKWGIFIPGNJ-NSUCVBPYSA-N 2-aminoethyl [(2R)-2,3-bis[(Z)-octadec-9-enoxy]propyl] hydrogen phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCC\C=C/CCCCCCCC SHCCKWGIFIPGNJ-NSUCVBPYSA-N 0.000 claims description 4
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 claims description 4
- LMMLLWZHCKCFQA-UGKPPGOTSA-N 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-prop-1-ynyloxolan-2-yl]pyrimidin-2-one Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C#CC)O[C@H](CO)[C@@H](O)[C@H]1O LMMLLWZHCKCFQA-UGKPPGOTSA-N 0.000 claims description 4
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 claims description 4
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-Bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 claims description 4
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 claims description 4
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-Methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 claims description 4
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 claims description 4
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 claims description 4
- OHBIZLMAUVTUPW-UHFFFAOYSA-N CCCCCCCCCCC(O)CN(CCCCC1OC(=O)C(CCCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)OC1=O)CC(O)CCCCCCCCC Chemical compound CCCCCCCCCCC(O)CN(CCCCC1OC(=O)C(CCCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)OC1=O)CC(O)CCCCCCCCC OHBIZLMAUVTUPW-UHFFFAOYSA-N 0.000 claims description 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims description 4
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 claims description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 4
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical compound N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 claims description 4
- PTJWIQPHWPFNBW-GBNDHIKLSA-N Pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 4
- HDZZVAMISRMYHH-LITAXDCLSA-N Tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims description 4
- DSNRWDQKZIEDDB-CLFAGFIQSA-N dioleoyl phosphatidylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-CLFAGFIQSA-N 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 125000003827 glycol group Chemical group 0.000 claims description 4
- 229960003786 inosine Drugs 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 2
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 claims description 2
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 claims description 2
- 210000004556 Brain Anatomy 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 210000002216 Heart Anatomy 0.000 claims description 2
- 210000000936 Intestines Anatomy 0.000 claims description 2
- 210000003734 Kidney Anatomy 0.000 claims description 2
- 210000004185 Liver Anatomy 0.000 claims description 2
- 210000001672 Ovary Anatomy 0.000 claims description 2
- 210000000952 Spleen Anatomy 0.000 claims description 2
- 210000002784 Stomach Anatomy 0.000 claims description 2
- 210000001550 Testis Anatomy 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 230000001886 ciliary Effects 0.000 claims description 2
- 230000003111 delayed Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 210000000056 organs Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- ANGOYQCNNLBDLX-UHFFFAOYSA-N CCCCCCCCCCC(O)CN(CCCC(C)C1OC(=O)C(OC1=O)C(C)CCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CC(O)CCCCCCCCC Chemical compound CCCCCCCCCCC(O)CN(CCCC(C)C1OC(=O)C(OC1=O)C(C)CCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CC(O)CCCCCCCCC ANGOYQCNNLBDLX-UHFFFAOYSA-N 0.000 claims 1
- 101000346496 DNAH5 Proteins 0.000 description 1
- 102000035639 human DNAH5 protein Human genes 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024010105A JP2024028651A (ja) | 2019-01-07 | 2024-01-26 | 原発性線毛機能不全症の治療のための組成物および方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962789414P | 2019-01-07 | 2019-01-07 | |
US62/789,414 | 2019-01-07 | ||
PCT/US2020/012529 WO2020146344A1 (en) | 2019-01-07 | 2020-01-07 | Composition and methods for treatment of primary ciliary dyskinesia |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024010105A Division JP2024028651A (ja) | 2019-01-07 | 2024-01-26 | 原発性線毛機能不全症の治療のための組成物および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022516356A JP2022516356A (ja) | 2022-02-25 |
JPWO2020146344A5 true JPWO2020146344A5 (de) | 2022-12-05 |
Family
ID=69423424
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021539435A Pending JP2022516356A (ja) | 2019-01-07 | 2020-01-07 | 原発性線毛機能不全症の治療のための組成物および方法 |
JP2024010105A Pending JP2024028651A (ja) | 2019-01-07 | 2024-01-26 | 原発性線毛機能不全症の治療のための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024010105A Pending JP2024028651A (ja) | 2019-01-07 | 2024-01-26 | 原発性線毛機能不全症の治療のための組成物および方法 |
Country Status (8)
Country | Link |
---|---|
US (3) | US20220087935A1 (de) |
EP (1) | EP3908597A1 (de) |
JP (2) | JP2022516356A (de) |
CN (1) | CN113412273A (de) |
AU (1) | AU2020206109A1 (de) |
CA (1) | CA3125588A1 (de) |
IL (1) | IL284480A (de) |
WO (1) | WO2020146344A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3463483T3 (da) * | 2016-05-27 | 2024-03-04 | Transcriptx Inc | Behandling af primær ciliedyskinesi med syntetisk messenger-RNA |
EP3908597A1 (de) * | 2019-01-07 | 2021-11-17 | Translate Bio, Inc. | Zusammensetzung und verfahren zur behandlung der primären ciliären dyskinesie |
EP4308703A1 (de) * | 2021-03-19 | 2024-01-24 | Recode Therapeutics, Inc. | Polynukleotidzusammensetzungen, zugehörige formulierungen und verfahren zur verwendung davon |
WO2023086893A1 (en) * | 2021-11-10 | 2023-05-19 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
JP4796062B2 (ja) | 2004-06-07 | 2011-10-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質封入干渉rna |
JP2009544754A (ja) | 2006-07-28 | 2009-12-17 | アプライド バイオシステムズ, エルエルシー | ジヌクレオチドmrnaキャップアナログ |
DK2094849T3 (en) * | 2006-11-09 | 2014-03-24 | Dynavax Tech Corp | LONG-TERM DISEASE MODIFICATION USING IMMUNSTIMULATORY OLIGONUCLEOTIDES |
WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
CA2984026C (en) | 2008-10-09 | 2020-02-11 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
KR102205886B1 (ko) | 2009-06-10 | 2021-01-21 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
ES2795110T3 (es) | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
CA3119789A1 (en) | 2011-10-27 | 2013-05-02 | Massachusetts Institute Of Technology | Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres |
DK2830595T3 (da) | 2012-03-29 | 2019-12-02 | Translate Bio Inc | Ioniserbare kationiske lipider |
EP3083556B1 (de) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen |
EP3450553B1 (de) | 2014-03-24 | 2019-12-25 | Translate Bio, Inc. | Mrna-therapie zur behandlung von augenerkrankungen |
EP3148552B1 (de) | 2014-05-30 | 2019-07-31 | Translate Bio, Inc. | Biologisch abbaubare lipide zur freisetzung von nukleinsäuren |
JP6594421B2 (ja) | 2014-06-25 | 2019-10-23 | アクイタス セラピューティクス インコーポレイテッド | 核酸の送達のための新規脂質および脂質ナノ粒子製剤 |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
WO2016118724A1 (en) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
CA2979695A1 (en) * | 2015-03-19 | 2016-09-22 | Translate Bio, Inc. | Mrna therapy for pompe disease |
JP6800410B2 (ja) | 2015-06-19 | 2020-12-16 | マサチューセッツ インスティテュート オブ テクノロジー | アルケニル置換2,5−ピペラジンジオン、および、対象または細胞に剤を送達するための組成物におけるそれらの使用 |
WO2017004143A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
WO2017075531A1 (en) | 2015-10-28 | 2017-05-04 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
EP3397613A1 (de) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipide und lipidnanopartikelformulierungen zur freisetzung von nukleinsäuren |
KR102617874B1 (ko) | 2016-03-30 | 2023-12-22 | 인텔리아 테라퓨틱스, 인크. | Crispr/cas 성분을 위한 지질 나노입자 제제 |
DK3463483T3 (da) | 2016-05-27 | 2024-03-04 | Transcriptx Inc | Behandling af primær ciliedyskinesi med syntetisk messenger-RNA |
WO2018089790A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved ice-based lipid nanoparticle formulation for delivery of mrna |
CA3041345A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
EP3592728A1 (de) * | 2017-03-07 | 2020-01-15 | Translate Bio, Inc. | Polyanionische verabreichung von nukleinsäuren |
EP3784285B1 (de) | 2018-04-25 | 2023-07-26 | Ethris GmbH | Kryoprotektive mittel für teilchenförmige formulierungen |
EP3908597A1 (de) * | 2019-01-07 | 2021-11-17 | Translate Bio, Inc. | Zusammensetzung und verfahren zur behandlung der primären ciliären dyskinesie |
-
2020
- 2020-01-07 EP EP20703340.8A patent/EP3908597A1/de active Pending
- 2020-01-07 CN CN202080012787.7A patent/CN113412273A/zh active Pending
- 2020-01-07 US US17/420,346 patent/US20220087935A1/en not_active Abandoned
- 2020-01-07 US US16/736,417 patent/US11559561B2/en active Active
- 2020-01-07 AU AU2020206109A patent/AU2020206109A1/en active Pending
- 2020-01-07 WO PCT/US2020/012529 patent/WO2020146344A1/en unknown
- 2020-01-07 JP JP2021539435A patent/JP2022516356A/ja active Pending
- 2020-01-07 CA CA3125588A patent/CA3125588A1/en active Pending
-
2021
- 2021-06-29 IL IL284480A patent/IL284480A/en unknown
-
2022
- 2022-12-06 US US18/062,435 patent/US20230226147A1/en active Pending
-
2024
- 2024-01-26 JP JP2024010105A patent/JP2024028651A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016535729A5 (de) | ||
JP2023169139A5 (de) | ||
JP2016535738A5 (de) | ||
JP2016539916A5 (de) | ||
JP2019073557A5 (de) | ||
JP2018511588A5 (de) | ||
US10138213B2 (en) | Stereochemically enriched compositions for delivery of nucleic acids | |
US20210205421A1 (en) | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency | |
US10584165B2 (en) | Methods and compositions for delivering mRNA coded antibodies | |
JP2017518371A5 (de) | ||
JP2017520563A5 (de) | ||
US7780882B2 (en) | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent | |
US20190192688A1 (en) | Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency | |
US20210401951A1 (en) | Mrna therapy for pompe disease | |
EP3318248B1 (de) | Ausgabe von mrna zur vermehrung von proteinen und enzymen bei humangenetischen erkrankungen | |
CA2838063C (en) | Cleavable lipids | |
JP2019533707A5 (de) | ||
US9034329B2 (en) | Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof | |
JP2018500303A5 (de) | ||
US20210186890A1 (en) | Process of preparing mrna-loaded lipid nanoparticles | |
US20210187122A1 (en) | Messenger rna therapy for the treatment of friedreich's ataxia | |
US20230190954A1 (en) | Composition and methods for treatment of primary ciliary dyskinesia | |
US11559561B2 (en) | Composition and methods for treatment of primary ciliary dyskinesia | |
JPWO2020146344A5 (de) | ||
JPWO2019232103A5 (de) |